Immunotherapy may reduce risk of heart diseases in arthritis patients

By  ,  Onlymyhealth editorial team
Jul 11, 2016

One new study reveals that the immunotherapy may reduce the risk of heart diseases in patients with rheumatoid arthritis.

Rheumatoid arthritis is a painful situation of swollen joints generally characterized by chronic pain in joints especially of hands and feet. The patients develop the risk of heart diseases with increasing stages of this autoimmune arthritis.


heart health


For the study, the team included 68 patients who had suffered from active rheumatoid arthritis for at least five years.

Patients were randomized to receive the combination of anti-TNF alpha and anti-IFN gamma plus standard disease-modifying therapy (38 patients) or placebo plus standard therapy (30 patients).

The findings showed that the combination of two anti cytokines containing extra-low doses of antibodies against tumor necrosis factor I (TNFI) and interferon gamma (IFN) could improve the efficacy of standard rheumatoid arthritis therapy and decrease heart disease risk.

Further, the patients taking the combination of anti cytokines had a lower rheumatoid arthritis disease activity score, as measured by the DAS28, 2 and more dramatic decreases in IL-1, IL-6 and TNF alpha than the group on standard therapy alone.

Rheumatoid arthritis is an autoimmune disease in which cytokines such as tumour necrosis factor-alpha (TNFI) and interferon-gamma (IFN), which normally protect the body, attack healthy cells leading to disease progression.


Image Source : Getty


Read More : Health News

Is it Helpful Article?YES1 Vote 778 Views 0 Comment
I have read the Privacy Policy and the Terms and Conditions. I provide my consent for my data to be processed for the purposes as described and receive communications for service related information.
This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK